The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to privosegtor, an experimental treatment from Oculis that aims to protect the vision of people experiencing acute optic neuritis. This condition, which involves inflammation of the optic nerve, is a common and often debilitating symptom of multiple sclerosis (MS) that can lead to vision […]
The post Privosegtor granted FDA breakthrough status for optic neuritis appeared first on Multiple Sclerosis News Today.
Source: multiplesclerosisnewstoday.com